An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages

Start Over | Back to Search Results

Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) Injection
Status: Currently in Shortage
»Date first posted: 03/07/2023
»Therapeutic Categories: Oncology

Advanced Accelerator Applications USA, Inc. (Reverified 03/21/2023)

Company Contact Information:
862-778-8300

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use 27 mCi/mL; Colorless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) ± 10% of lutetium Lu 177 vipivotide tetraxetan (NDC 69488-010-61)	Availability: Limited; Estimated Duration of Supply Shortage: Approximately four months	There are challenges in meeting demand and no therapeutic equivalents are available. For more information, please see the attached: Novartis Update for Patients on Supply of PLUVICTO and FAQs	Other

Top